Sentences with phrase «patented by pharmaceutical companies»

Synthetic hormones have a different chemical structure, which allows them to be patented by pharmaceutical companies.

Both progestins and the «natural» progesterone derive from diosgenin, but because a natural hormone can not be patented by a pharmaceutical company, an alteration of the molecule was required in order to secure patent rights... hence progestins.

Not exact matches

Big biotech and pharma companies are absolutely dependent on being able to successfully innovate by partnering with and acquiring disruptive startups because of the nature of the patent cliff in pharmaceuticals.

It is hard to believe, for example, that Canada could not in the end find common ground with the US on some extension of patent protection for pharmaceuticals, since it was able to do so in the just - completed negotiations with the EU, or that an extension of the term of copyright protection from 50 to 70 years from the agreed baseline would have much if any real practical impact on Canada although it would be seen as a gain by the US given the heavy copyright portfolios of US entertainment companies, allowing them an additional period of time to exploit their copyrighted content.

An Indian generic drug company on Monday urged a federal appeals court to reconsider a recent decision that revived a patent infringement case against Google LLC, saying the ruling could spur «vexatious lawsuits» by makers of brand - name pharmaceutical products.

The test called SkimuneTM, which is trademarked and has a patent pending, has been successfully tested by a number of large pharmaceutical companies on drugs in development and provides a reliable result within two weeks.

No pharmaceutical company will make billions from this, and none of them will ever be able to become the gate keeper of this remedy by getting a patent to monopolize apple cider vinegar.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and / or regulatory actions.

Specifically, they estimate that about $ 8.4 billion in global profits came directly from patents held by publicly traded United States companies in 1997, rising to about $ 9.3 billion in 1999, with two - thirds of the profits going to chemical and pharmaceutical companies.

In particular, Eli Lilly claimed that the development of the «promise doctrine» in Canadian patent law led to the invalidation of patents protecting its drugs atomoxetine (Strattera ®) and olanzapine (Zyprexa ®) by Canadian courts, and that this doctrine was radically new, arbitrary, and discriminatory against pharmaceutical companies.

In addition, we are well - versed in the intellectual property issues faced by pharmaceutical companies and medical device manufacturers, and regularly advise on patent strategy, freedom to operate, opinion work, and licensing, manufacturing, and distribution agreements.

On the cost efficiency — or not — of our health system, an interesting article by Australian researchers was published by The Conversation explaining the concept of patent «evergreening» — a strategy pharmaceutical companies use to keep the cost of medicines (and their profits) high.